DAVINCI BIO, INC.

Fremont, CA · Medtech · Defunct

UltraFISH+, a spatial single-cell analysis platform using fluorescence in situ hybridization to profile and map cell types across tissues at single-cell resolution

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Headquarters
Fremont, CA
Total capital
$1.1M
Federal grants
$1.1M
3 awards · 2018–2021
Rank in peer group#66 of 79
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
6 pending

Capital timeline

2018201920202021FEDERAL ↑EQUITY ↓Cumulative $1.1M$338K$499K$300K
2018201920202021FEDERAL ↑EQUITY ↓Cumulative $1.1M$338K$499K$300K

Latest events

  • Federal grantHealth and Human S · Phase I · UltraFISH+ for Single-cell Spatial Cell Type Analysis$300K
  • Federal grantHealth and Human S · Phase I · High Capacity UltraFISH for Single-cell Spatial Transcriptomics$499K
  • Federal grantHealth and Human S · Phase I · Rainbow UltraFISH: Rapid Sequential RNA FISH for Single-cell Gene Expression Analysis$338K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 79 peers

Line = median

Medtech · Instrument

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 6
  • PendingHigh Capacity Molecule DetectionUSPTOApplication 16918958
  • PendingHigh Capacity Molecule DetectionUSPTOApplication PCTUS2020040474
  • PendingMethods For In Situ Detection Of Dna And RnaUSPTOApplication PCTUS2020037414
Show all 6 patent records
  • High Capacity Molecule DetectionMar 11, 2021 · Application 16918958Pending
  • High Capacity Molecule DetectionApplication PCTUS2020040474Pending
  • Methods For In Situ Detection Of Dna And RnaApplication PCTUS2020037414Pending
  • High Capacity Molecule DetectionApplication 62925197Pending
  • High Capacity Molecule DetectionApplication 62869502Pending
  • Methods for In Situ Detection of DNA and RNAApplication 62860366Pending
  • CARTOX, LLCSimilar federal contract value in Medtech · null in contracts
  • BRAINSYMPHONICS, LLCSimilar federal contract value in Medtech · null in contracts
  • VIRTUAL PHANTOMS, INC.Similar federal contract value in Medtech · null in contracts
  • CYTOVERIS INCSimilar federal contract value in Medtech · null in contracts
  • Potrero Medical, Inc.Similar federal contract value in Medtech · null in contracts
  • ALDATU BIOSCIENCES INCSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .